Gastrointestinal Cancer CPG Mini-Module – Immunotherapy biomarkers in the gastrointestinal tract

The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, these on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.   

Kristen K. Ciombor, MD, MSCI, of Vanderbilt Ingram Cancer Center, Vanderbilt University, presents an overview of tumor-agnostic biomarkers including MSI-H/dMMR, POLE/POLD1 mutations, and TMB and the caveats of these biomarkers in the context of gastrointestinal cancers. Data from key clinical studies of these biomarkers are also discussed.

Run time: Approximately 11 minutes

Target Audience
Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists. 

SITC Online Education Disclaimer 

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 09/07/2023). 

The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.